

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C07D 501/04, 501/12, 501/34		A1	(11) International Publication Number: WO 00/66594 (43) International Publication Date: 9 November 2000 (09.11.00)
<p>(21) International Application Number: PCT/EP00/03941</p> <p>(22) International Filing Date: 3 May 2000 (03.05.00)</p> <p>(30) Priority Data: A 799/99 5 May 1999 (05.05.99) AT</p> <p>(71) Applicant (<i>for all designated States except US</i>): BIOCHEMIE GESELLSCHAFT M.B.H. [AT/AT]; A-6250 Kundl (AT).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (<i>for US only</i>): GREIL, Julia [AT/AT]; Lende 179 b, A-6233 Kramsach (AT). LUDESCHER, Johannes [AT/AT]; Kleinsöll 101, A-6252 Breitenbach (AT). TOTSCHNIG, Klaus [AT/AT]; Biochemiestrasse 44, A-6250 Kundel (AT). WOLF, Siegfried [AT/AT]; Bruggerstrasse 4, A-6230 Brixlegg (AT).</p> <p>(74) Agent: BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Department, CH-4002 Basel (CH).</p>		<p>(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p>(54) Title: CRYSTALLINE BETA-LACTAM INTERMEDIATE</p> <p>(57) Abstract</p> <p>Crystalline 7-[2-(2-formylaminothiazol-4-yl)- 2-(Z)-(methoxyimino)acetamido]- 3-methoxy-methyl-3- cephem-4-carboxylic acid- 1-(isopropoxycarbonyloxy)ethyl ester and its use.</p>			

FOR THE PURPOSES OF INFORMATION ONLY


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CI	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

Crystalline beta-lactam intermediate

The present invention relates to β -lactams, particularly to cefpodoxime proxetil, of formula




5

e.g. described in The Merck Index, Twelfth Edition, Item 1991; more particularly to a process for the adjustment, e.g. change, of the diastereoisomeric ratio of the two existing diastereoisomers being with respect to the carbon atom attached to the oxygen of the ester group in the carboxyl ester group in position 4 of the ring system (marked with a star (*) in formula II). A diastereoisomeric ratio B/(A+B) of cefpodoxime proxetil currently on the market may be around 0.53. B is the more apolar of the two diastereoisomers. Because of different bioavailability of these individual diastereoisomers a commercial form for oral administration of cefpodoxime proxetil has to be within a defined ratio B/(A+B). A diastereoisomeric ratio B/(A+B) of 0.5 to 0.6 has been found to be bioequivalent with a commercial form. Determination of the diasterisomeric content of the diastereoisomers A and B in cefpodoxime proxetil may be carried out by HPLC, e.g. according to a method as described in Pharmacopeial Forum, Vol. 23, No. 4, p. 4388 ff (1997), the content of which is incorporated herein by reference, e.g. from which a diastereoisomeric ratio B/(A+B) and A/(A+B) may be calculated.

One process in the production of cefpodoxime proxetil may be carried out via acylation of 7-amino-3-methoxy-methyl-3-cephem-4-carboxylic acid-1-(isopropoxycarbonyloxy)ethyl-ester of formula


25

- 2 -



III

with activated Z-2-(methoxyimino)-2-(2-formylaminothiazol-4-yl)-acetic acid to obtain 7-[2-(2-formylaminothiazol-4-yl)-2-(Z)-(methoxyimino)acetamido]-3-methoxymethyl-3-cephem-4-carboxylic acid 1-(isopropoxycarbonyloxy)ethyl ester (N-formyl cefpodoxime proxetil) of formula




10 It was found that a mixture of diastereoisomers of a compound of formula I may be obtained in a diastereoisomeric ratio $B/(A+B)$ of 0.40 to below 0.50. The reaction for splitting off the formyl group in a compound of formula I obtained to obtain cefpodoxime proxetil may have no significant influence on the diastereoisomeric ratio $B/(A+B)$ and consequently $B/(A+B)$ in cefpodoxime proxetil obtained from a process as described above 15 may be outside of 0.5 to 0.6.


Surprisingly a simple process has now been found wherein cefpodoxime proxetil may be obtained in high purity; e.g. in a diastereoisomeric ratio which is 0.4 to 0.7, e.g. 0.5 to 0.6.

20 A compound of formula I may be produced, e.g. in conventional manner and e.g. as follows:

The carboxylic acid group in position 4 of the ring system of 7-amino-3-methoxymethyl-3-cephem-4-carboxylic acid (AMCA), e.g. of formula



which is a known compound and obtainable, e.g. according to a method as conventional,
 5 may be esterified to obtain a compound of formula III. This may be effected according to a
 method as conventional, e.g. by reacting AMCA with a compound of formula



10 wherein X denotes a leaving group, e.g. a conventional leaving group, such as a
 halogenide, e.g. an iodide; e.g. in the presence of a solvent (system). Esterification may
 be effected e.g. in conventional solvent (system), e.g. organic solvent, such as ketones,
 e.g. acetone; nitriles, e.g. acetonitrile; acetamides, e.g. dimethylacetamide; and
 halogenated hydrocarbons, e.g. dichloromethane; and e.g. in the presence of a base; e.g.
 15 an amidine, such as 1,5-diazabicyclo(4,3,0)non-5-ene (DBN) or
 1,8-diazabicyclo(5,4,0)undec-7-ene (DBU); or a guanidine, e.g. a linear guanidine, such as
 tetramethylguanidine, pentamethylguanidine, tetraethylguanidine,
 tetramethylethylguanidine and tetramethylbenzylguanidine or a cyclic or bicyclic guanidine,
 e.g. 1,5,7-triazabicyclo-(4,4,0)-dec-5-ene, and 7-methyl, 7-ethyl, 7-benzyl and 7-phenyl
 20 derivatives thereof. A compound of formula III obtained may be isolated, if desired, e.g.
 according to a method as conventional.

The amine group in position 7 of the ring structure of a compound of formula III, e.g.
 obtained as described above, e.g. with or without isolation from a corresponding reaction
 25 mixture, preferably without isolation, may be acylated e.g. according to a method as
 conventional. This may be effected e.g. by reaction of a compound of formula III obtained
 in the esterification reaction, with activated Z-(2-formylaminothiazol-4-yl)-methoxyimino
 acetic acid, e.g. including an ester or an acid halogenide, such as Z-(2-formylaminothiazol-
 4-yl)-methoxyimino-acetic acid chloride, e.g. in the form of a salt, e.g. a hydrochloride,
 30 including activated Z-(2-formamidothiazol-4-yl)-methoxyimino acetic acid obtainable by a
 Vilsmeier reaction. Vilsmeier activated Z-(2-formamidothiazol-4-yl)-methoxyimino acetic

acid may be produced e.g. in conventional manner, e.g. in situ in the reaction mixture e.g. by treating Z-(2-formamidothiazol-4-yl)-methoxyimino acetic acid with phosphoroxyhalogenide, e.g. chloride, e.g. under Vilsmeier reaction conditions.

- 5 Acylation may be carried out in organic solvent (system), including e.g. carboxylic acid esters, e.g. acetates, such as ethyl acetate; halogenated hydrocarbons, e.g. aliphatic, such as dichloromethane, e.g. in dichloromethane; in the presence of a nitrile or a ketone; e.g. in the presence of an amide, e.g. N,N-dimethylformamide (DMF); e.g. in the presence of pH adjustment. pH Adjustment may be effected e.g. by addition of a base, such as an inorganic base, e.g. a carbonate or bicarbonate, e.g. sodium and potassium, or e.g. of an, e.g. weakly, basic anionic exchange resin, to obtain a pH of ca. 2.5 to 8.0. Surprisingly pH adjustment may alternatively also be avoided. A compound of formula I may be obtained in the reaction mixture. According to the present invention a compound of formula I may be obtained in crystalline form.
- 15 A compound of formula I in crystalline form may be produced as follows: N-formyl cefpodoxime proxetil may be suspended or dissolved in a nitrile, or in a ketone; e.g. including mixtures thereof; and may crystallise, e.g. and water may be added to the mixture.
- 20 A nitrile, e.g. a (C₂₋₅)nitrile, includes for example acetonitrile, propionitrile or butyronitrile, preferably acetonitrile. A ketone, e.g. a (C₂₋₄)ketone, includes for example acetone or methyl ethyl ketone, preferably acetone. The temperature during crystallisation is not critical. A compound of formula I may crystallise at, below, or higher than room temperature, e.g. at room temperature; in an ice-bath, or up to 70°C. Temperatures of 20 to 40°C are preferred.
- 25 Crystallisation of a compound of formula I from organic solvent comprising a nitrile or a ketone may result in a mixture of diastereoisomers of a compound of formula I in a diastereoisomeric ratio B/(A+B) of 0.4 to 0.7.
- 30 We have found surprisingly that water may have an influence in respect with a desired diastereoisomeric ratio of N-formyl cefpodoxime diastereoisomers and that a diastereoisomeric ratio of 0.5 to 0.6 may be adjusted by addition of appropriate amounts of water to a mixture containing a compound of formula I and a nitrile or a ketone.

Alternatively, N-formyl cefpodoxime proxetil may be suspended or dissolved, preferably dissolved, in organic amide or urea, preferably in organic amide, for example DMF, or in organic amide in combination with a ketone, for example acetone; a nitrile, for example acetonitrile; an ester, for example ethyl acetate; or a halogenated hydrocarbon, for example dichloromethane, e.g. dichloromethane in combination with a nitrile or a ketone. If not already present a nitrile or a ketone, e.g. and water, is added to the mixture obtained. A compound of formula I may crystallise and may be obtained in crystalline form, e.g. a mixture of diastereoisomers of a compound of formula I in a diastereoisomeric ratio B/(A+B) of 0.4 to 0.7, such as 0.5 to 0.6 may be obtained.

The ratio of water/organic solvent is critical, not only for crystallisation, but for a desired diastereoisomeric ratio and for a high purification effect of a compound of formula I. Higher amount of organic solvent may result in a higher diastereoisomeric ratio B/(A+B). E.g. from pure acetonitrile as a solvent a compound of formula I may be obtained in a diastereoisomeric ratio B/(A+B) of 0.63.

If too much water is present, the purification effect in the crystallisation step may be insufficient. An appropriate amount of water may easily be found out, e.g. by determining purity and the diastereoisomeric ratio B/(A+B) for different amounts of water present. Preferred solvent ratios include e.g. 2 to 15 ml, preferably 3 to 10 ml of a nitrile, preferably acetonitrile, and 5 to 80 ml, preferably 10 to 50 ml of water, based on 1 g of a compound of formula I. The solvent ratio may also depend whether and in which amount an organic amide e.g. DMF is present. E.g. DMF may be present in the solvent system, e.g. 1 to 20 ml, preferably 2 to 15 ml; DMF per g of a compound of formula I.

If a compound of formula I is crystallised from a ketone, e.g. acetone and water, preferred amounts of acetone and water include 3 to 15 ml, preferably 3 to 10 ml of a ketone, e.g. acetone; and 10 to 40 ml, preferably 15 to 30 ml of water; per g of a compound of formula I.

N-formyl cefpodoxime proxetil may also be produced directly from a reaction mixture wherein N-formyl cefpodoxime is obtained, e.g. as follows:

To a mixture containing a compound of formula I, e.g. obtained in a corresponding reaction an organic amide, e.g. DMF or urea is added, e.g. if not already present; and solvent is removed, e.g. by distillation, evaporation. The residue obtained is mixed with a nitrile or a ketone; e.g. and water. Alternatively, if acylation is carried out in dichloromethane, a nitrile

or a ketone may be added after removal of the solvent; e.g. and water may be added to the residual mixture obtained. N-Formyl cefpodoxime proxetil may crystallise and may be isolated from the reaction mixture, e.g. according to a method as conventional.

Crystalline N-formyl cefpodoxime proxetil in crystalline form is new.

5

In one aspect the present invention provides a compound of formula I in crystalline form.

Production of a compound of formula I in crystalline form may have a high purification effect, e.g. in (part of) a production sequence from AMCA to N-formyl cefpodoxime.

10

We have surprisingly additionally found, that N-formyl cefpodoxime produced according to the present invention may crystallise in a diastereoisomeric ratio B/(A+B) of 0.5 to 0.6.

15

In another aspect the present invention provides a process for the production of a compound of formula I in crystalline form, e.g. a mixture of diastereoisomers of a compound of formula I, comprising crystallizing a compound of formula I in organic solvent comprising a nitrile, e.g. a (C₂₋₄)nitrile; or a ketone, e.g. a (C₃₋₅)ketone; e.g. in the presence of water, e.g. wherein the diastereoisomeric ratio B/(A+B), wherein B is the more apolar of the two diastereoisomers, is 0.5 to 0.6, the diastereoisomers being with respect with the carbon atom marked with a star in formula I.

20

In still another aspect the present invention provides the use of crystalline N-formyl cefpodoxime proxetil in the purification of cefpodoxime proxetil, e.g. in the form of a mixture of diastereoisomers of a compound of formula I, wherein the diastereoisomeric ratio B/(A+B), wherein B is the more apolar of the two diastereoisomers, is 0.5 to 0.6, the diastereoisomers being with respect with the carbon atom marked with a star in formula I.

25

In another aspect the present invention provides a process for the adjustment, e.g. change, of the diastereoisomeric ratio B/(A+B) wherein B is the more apolar of the two diastereoisomers; of a mixture of diastereoisomers of cefpodoxime proxetil, e.g. adjusting a diastereoisomeric ratio B/(A+B) to 0.5 to 0.6; the diastereoisomers being with respect with the carbon atom marked with a star in formula I, comprising crystallizing a compound of formula I from a mixture comprising water and either a nitrile, e.g. a (C₂₋₅)nitrile, or a

ketone, e.g. a (C₃₋₅)ketone; e.g. including mixtures thereof; and converting the crystalline compound of formula I obtained into cefpodoxime proxetil.

In a further aspect the present invention provides a process for the purification of 5 cefpodoxime proxetil, comprising producing a compound of formula I as defined in claim 1 and crystallizing in the presence of a nitrile or a ketone and converting a crystalline compound of formula I into cefpodoxime proxetil.

In still another aspect the present invention provides a process for the production of a 10 mixture of diastereoisomers of cefpodoxime proxetil of formula II in a diastereoisomeric ratio B/(A+B), wherein B is the more apolar of the two diastereoisomers, of 0.5 to 0.6, the diastereoisomers being with respect with the carbon atom marked with a star in formula II, comprising producing a mixture of diastereoisomers of a compound of formula I by 15 acylating a compound of formula III with activated Z-(2-formamidothiazol-4-yl)-methoxyimino acetic acid, removing solvent from the reaction mixture obtained, crystallizing a compound of formula I in the residue obtained in the presence of a nitrile or a ketone, e.g. in the presence of water; isolating a compound of formula I in crystalline form and converting a compound of formula I by splitting off the formyl group from the 20 amino group attached to the thiazolyl group, to obtain a compound of formula I, in the form of a diastereoisomeric mixture in a ratio of B/(A+B) of 0.5 to 0.6, e.g. wherein a compound of formula III is produced by esterifying 7-amino-3-methoxymethyl-3-cephem-4-carboxylic acid with a compound of formula V wherein X denotes a leaving group.

Advantages of a process according to the present invention includes e.g.:

- 25 – Crystallisation of N-formyl cefpodoxime proxetil which may surprisingly carried out according to a process according to the present invention may have a strong purification effect in e.g. part of the reaction sequence of producing cefpodoxime proxetil e.g. starting from AMCA, or AMCA-ester.
- A process according to the process of the present invention may be used on technical 30 scale.
- A desired diastereoisomeric ratio B/(A+B) may be adjusted in the production of cefpodoxime proxetil, e.g. of 4 to 7 such as of 5 to 6.

In still another aspect the present invention provides a crystalline 7-[2-(2-formylamino-thiazol-4-yl)-2-(Z)-(methoxyimino)acetamido]-3-methoxymethyl-3-cephem-4-carboxylic acid-1-(isopropoxycarbonyloxy)ethyl ester of formula I as a diastereoisomeric mixture of formula I (*signifies the asymmetric centre) and a process for the production of the 5 diastereoisomeric mixture of formula I, whereby a compound of formula III is acylated with a reactive derivative of (2-N-formylaminothiazol-4-yl)-2-(Z)-(methoxyimino)-acetic acid and the compound of formula I is crystallised in water and a (C₁₋₄)nitrile or water and a (C₃₋₅)ketone, e.g. whereby the compound of formula III is produced by the esterification of 10 7-amino-3-methoxymethyl-3-cephem-4-carboxylic acid of formula IV with a compound of formula V wherein X signifies a leaving group, in the presence of a base.

In the following examples all temperatures are given in degrees celsius.

The following abbreviations are used:

15 DMF: N,N-dimethylformamide
AMCA: 7-amino-3-methoxymethyl-3-cephem-4-carboxylic acid
DBU: 1,8-diazabicyclo(5,4,0)undec-7-ene
AMCA-ester: 7-amino-3-methoxymethyl-3-cephem-4-carboxylic acid-1-(isopropoxy-
carbonyloxy)ethyl ester
20 N-Formyl cefpodoxime proxetil: 7-[2-(2-formylaminothiazol-4-yl)-2-(Z)-(methoxy-
imino)acetamido]-3-methoxymethyl-3-cephem-4-carboxylic acid 1-(isopropoxy-
carbonyloxy)ethyl ester
Cefpodoxime proxetil: 7-[2-(2-aminothiazol-4-yl)-2-(Z)-(methoxyimino)acetamido]-3-
methoxymethyl-3-cephem-4-carboxylic acid-1-(isopropoxycarbonyloxy)ethyl ester

Example 1:

Crystallisation of N-formyl cefpodoxime proxetil from acetone/water

3 g of amorphous N-formyl cefpodoxime proxetil with a diastereoisomeric ratio B/(A+B) of 0.51 and a HPLC purity of 97% are dissolved in a mixture of 6 ml of DMF and 18 ml of acetone. The solution is heated to 40° and 20 ml of water are added while stirring and after seeding further ca. 40 ml of water are added dropwise while stirring. Crystallisation occurs and the crystalline precipitate is filtrated off and dried. N-Formyl cefpodoxime proxetil in crystalline form is obtained comprising a mixture of diastereoisomers with a diastereoisomeric ratio of B/(A+B) = 0.58.

10 Seed crystals are obtained in preliminary crystallisation tests.

Example 2:

Crystallisation of N-formyl cefpodoxime proxetil from acetonitrile/water

a) Is carried out as example 1, with the following differences:

15 – 15 ml acetonitrile instead of 18 ml acetone
– room temperature instead of heating to 40°
– adding further 30 ml water instead of 40 ml.

N-Formyl cefpodoxime proxetil in crystalline form is obtained comprising a mixture of diastereoisomers with a diastereoisomeric ratio B/(A+B) = 0.56. HPLC purity: 98.7%

b) Is carried out as example 2a), with the following differences:

20 – 3 ml of DMF and 10 ml of acetonitrile instead of 6 ml of DMF and 15 ml of acetonitrile
– 12 ml of water instead of 20 ml
– adding further 38 ml of water instead of 40 ml.

25 N-Formyl cefpodoxime proxetil in crystalline form is obtained comprising a mixture of diastereoisomers with a diastereoisomeric ratio B/(A+B) = 0.53. HPLC purity: 98.1%

Example 3:

Crystallisation of N-formyl cefpodoxime proxetil from reaction solutions

30 a) Preparation of AMCA-ester

SOLUTION A):

A suspension of 50 g of AMCA in 1000 ml of acetone is mixed with 28.8 g of DBU and the mixture obtained is stirred at room temperature. The solution obtained is cooled to 0°, mixed with 437 g of a 14% toluene solution of 1-iodoethyl-isopropyl carbonate and

stirred for ca. 4 hours at ca. 0°. A suspension is obtained and the solid is filtrated off. The filtrate is poured onto water/conc. HCl, and the pH of the mixture obtained is adjusted to 1.0. From the two-phase system obtained, the organic phase is separated off and extracted with water. 1000 ml of ethyl acetate is added to the aqueous phase obtained, and a pH of 8.2 is adjusted with 5N NaOH. The aqueous phase of the two-phase system obtained is separated off and extracted with ethyl acetate. The organic phase obtained is washed with NaHCO₃ solution and water and dried over MgSO₄. A solution of AMCA-ester in 1100 ml of ethyl acetate (SOLUTION A) is obtained with a content of 5.7% of AMCA-ester in a diastereoisomeric ratio of B/(A+B) = 0.49.

10 b) Activation of (2-N-formylaminothiazol-4-yl)-2-(Z)-(methoxyimino)-acetic acid
SOLUTION B):

A mixture of 21.4 ml of ethyl acetate, 5.8 ml of DMF, 1.13 ml of phosphorus oxychloride and 2.82 g of (2-N-formylaminothiazol-4-yl)-2-(Z)-(methoxyimino)-acetic acid is stirred for ca. one hour at ca. -10°. The solution obtained is cooled to ca. -25°.

15 c) Preparation of N-formyl cefpodoxime proxetil

To a solution of 4.29 g of KHCO₃ in 41.1 ml of ice-cooled water, 93 ml of SOLUTION A) containing 0.0124 mol of AMCA-ester, and SOLUTION B), cooled to -25°, are added in such a way that the temperature of the mixture remains at ca. 5°.

20 The mixture obtained is stirred for ca. 30 minutes at ca. 5°. The phases of the two-phase system obtained are separated. 20 ml of water are added to the organic phase and the pH is adjusted to 7.1 with KHCO₃ while stirring. The phases of the two-phase system obtained are separated. Water is added to the organic phase, and the pH is adjusted to ca. 1.3 with 5 m H₂SO₄. The mixture obtained is stirred, the phases of the two-phase system are separated and the organic phase is washed with water and treated with 6.3 ml of DMF. Ethyl acetate is removed from the mixture obtained and the evaporation residue is mixed with 23 ml of acetonitrile. The mixture obtained is heated to 40° and 27 ml of water are added dropwise. After addition of seeds a further 90 ml of water at 40° while stirring. The obtained crystalline precipitate is filtrated off from the reaction mixture and dried. N-Formyl cefpodoxime in crystalline form and in the form of a diastereoisomeric mixture is obtained with a diastereoisomeric ratio of B/(A+B) = 0.50 and an HPLC purity of 97.8%.

30 Seed crystals are obtained in preliminary crystallisation tests.

Example 4:**Crystallisation of N-formyl cefpodoxime proxetil from reaction solutions****a) AMCA-ester****SOLUTION A)**

A suspension of 50 g of AMCA in 500 ml of dichloromethane is mixed with 28.8 g of DBU and the mixture obtained is stirred at room temperature. The solution obtained is cooled to ca. 0°, mixed with 437 g of a 14% toluene solution of 1-iodoethyl-isopropyl carbonate and the mixture obtained is stirred for ca. 4 hours at ca. 0°. The mixture obtained is mixed with 1000 ml of toluene and the mixture obtained is filtered. The filtrate obtained is worked up according to the method as described in example 3a). A solution of AMCA-ester in toluene is obtained with an AMCA-ester content of 5.8% in the form of a diastereoisomeric mixture with a diastereoisomeric ratio of B/(A+B) = 0.49.

15 b) (2-N-formylaminothiazol-4-yl)-2-(Z)-(methoxyimino)-acetic acid chloride in the form of a hydrochloride

A suspension of 60 g of (2-N-formylaminothiazol-4-yl)-2-(Z)-(methoxyimino)-acetic acid in 600 ml of dichloromethane, cooled to ca. -10° is treated with 60 g of PCl_5 while stirring, at a temperature below ca. -5°. The suspension obtained is stirred for ca. 90 minutes at ca. -5° to 0°. A precipitate forms in the reaction mixture obtained and is filtrated off, washed and dried. Solid 2-N-formylaminothiazol-4-yl)-2-(Z)-methoxyimino acetic acid chloride in the form of a hydrochloride is obtained.

c) N-Formyl cefpodoxime proxetil

To a solution of 2.73 g of KHCO_3 in 46.6 ml of ice-cooled water are added 89.2 ml of SOLUTION A) containing 0.0124 mol of AMCA-ester. The mixture obtained is diluted with 8.6 ml of ethyl acetate and 3.45 g of (2-N-formylaminothiazol-4-yl)-methoxyimino)-acetic acid chloride-hydrochloride, produced according to example 4b), are added in such a way that the temperature of the mixture does not exceed ca. 5°. The mixture obtained is stirred for ca. 30 minutes at ca. 5°. The phases of the two-phase system obtained are separated. To the organic phase 23.3 ml of water and 0.5 ml of DMF are added and the pH is adjusted to ca. 7.5 with KHCO_3 . The phases of the two-phase system obtained are separated, 23.3 ml of water and 0.5 ml of DMF are added to the organic phase, and the pH is adjusted to 1.5 with 5 m H_2SO_4 . The phases of the two-phase system obtained are separated and the organic phase is washed with water

and DMF. 6.3 ml of DMF are added to the organic phase obtained and ethyl acetate is removed by evaporation. The evaporation residue obtained is mixed with 6.3 ml of DMF and 45 ml of acetonitrile. The mixture obtained is heated to ca. 35° and 55 ml of water and a further 179 ml of water are added after seeding dropwise over the course of 40 minutes. The crystalline precipitate from the suspension obtained is filtrated off, washed with water and dried. N-Formyl cefpodoxim proxetil in the form of a diastereoisomeric mixture with a diastereoisomeric ratio of $B/(A+B) = 0.51$ in an HPLC purity of 98.0% is obtained.

Seed crystals are obtained in preliminary crystallisation tests.

10


Example 5:**Cefpodoxime proxetil**

20 ml of methanol and 0.48 ml of conc. H_2SO_4 are mixed and 4.0 g of N-formyl cefpodoxime proxetil obtained according to example 3c) are added to the mixture obtained. A solution is obtained, is stirred at room temperature for ca. 85 minutes, and is added dropwise, whilst stirring to a solution of 2 g of $KHCO_3$ in 200 ml of water. Cefpodoxime proxetil precipitates, is isolated, washed with water and dried. Cefpodoxime proxetil in the form of a diastereoisomeric mixture with a diastereoisomeric ratio of $B/(A+B) = 0.51$ and of an HPLC purity of 97.4% is obtained.

20

Patent Claims

1. A compound of formula



5

in crystalline form.

10 2. A mixture of diastereoisomers of a compound of formula I, as defined in claim 1, wherein the diastereoisomeric ratio B/(A+B), wherein B is the more apolar of the two diastereoisomers, is 0.5 to 0.6, the diastereoisomers being with respect with the carbon atom marked with a star in formula I, in crystalline form.

15 3. A process for the production of a compound of formula I in crystalline form comprising crystallizing a compound of formula I in organic solvent comprising a nitrile, or a ketone.

20 4. A process for the production of a mixture of diastereoisomers of a compound of formula I, as defined in claim 1, wherein the diastereoisomeric ratio B/(A+B), wherein B is the more apolar of the two diastereoisomers, is 0.5 to 0.6, the diastereoisomers being with respect with the carbon atom marked with a star in formula I, in crystalline form, comprising crystallizing a compound of formula I in organic solvent comprising a nitrile or a ketone; or mixtures thereof; and water.

25 5. Use of crystalline N-formyl cefpodoxime proxetil in the purification of cefpodoxime proxetil.

6. A process for the purification of cefpodoxime proxetil comprising producing a compound of formula I as defined in claim 1 and crystallizing in the presence of a nitrile or a ketone and converting a crystalline compound of formula I into cefpodoxime proxetil.


5

7. A process for the adjustment of the diastereoisomeric ratio B/(A+B) wherein B is the more apolar of the two diastereoisomers; of a mixture of diastereoisomers of cefpodoxime proxetil, the diastereoisomers being with respect with the carbon atom marked with a star in formula I, comprising crystallizing a compound of formula I from a mixture comprising water and either a nitrile or a ketone; or mixtures thereof; and converting a crystalline compound of formula I into cefpodoxime proxetil.

10


8. A process for the production of a mixture of diastereoisomers of cefpodoxime proxetil of formula

15




20

in a diastereoisomeric ratio B/(A+B), wherein B is the more apolar of the two diastereoisomers, of 0.5 to 0.6, the diastereoisomers being with respect with the carbon atom marked with a star in formula II, comprising producing a mixture of diastereoisomers of a compound of formula



by acylating a compound of formula



III

5

with activated Z-(2-formamidothiazol-4-yl)-methoxyimino acetic acid, removing solvent from the reaction mixture obtained, crystallizing a compound of formula I in the residue obtained in the presence of a nitrile or a ketone, e.g. in the presence of water; isolating a compound of formula I in crystalline form and converting a compound of formula I by splitting off the formyl group from the amino group attached to the thiazolyl group, to obtain a compound of formula I, in the form of a diastereoisomeric mixture in a ratio of B/(A+B) of 0.5 to 0.6.

10 15 9. A process according to claim 8 wherein a compound of formula III is produced by esterifying 7-amino-3-methoxymethyl-3-cephem-4-carboxylic acid with a compound of formula



V


20

wherein X denotes a leaving group.

10. A process according to any one of claims 3 to 9 wherein a nitrile is acetonitrile.

11. A process according to any one of claims 3 to 9 wherein a ketone is acetone.


12. Crystalline 7-[2-(2-formylaminothiazol-4-yl)-2-(Z)-(methoxyimino)acetamido]-3-methoxymethyl-3-cephem-4-carboxylic acid-1-(isopropoxycarbonyloxy)ethyl ester of formula



as a diastereoisomeric mixture of formula I (* signifies the asymmetric centre).

10


13. Process for the production of the diastereoisomeric mixture of formula I, whereby a compound of formula




15

is acylated with a reactive derivative of (2-N-formylaminothiazol-4-yl)-2-(Z)-(methoxyimino)-acetic acid and the compound of formula I is crystallised in water and a (C_{1-4})nitrile or water and a (C_{3-5})ketone, e.g. whereby the compound of formula III is produced by the esterification of 7-amino-3-methoxymethyl-3-cephem-4-carboxylic acid of formula

20



with a compound of formula



5 wherein X signifies a leaving group, in the presence of a base.

INTERNATIONAL SEARCH REPORT

It _____ Application No
PCT/EP 00/03941

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D501/04 C07D501/12 C07D501/34

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 99 35149 A (GREIL JULIA ;BIOCHEMIE GMBH (AT); TOTSCHNIG KLAUS (AT); LUDESCHER) 15 July 1999 (1999-07-15) claims 1,4,8-11; example 1 -----	1-13
A	US 4 486 425 A (NAKAO HIDEO ET AL) 4 December 1984 (1984-12-04) method 1 column 5, line 4 - line 6 -----	1-13
A	US 5 461 043 A (FISCHER GERD ET AL) 24 October 1995 (1995-10-24) examples 7-9 -----	1-13
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

16 October 2000

25/10/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Härtinger, S

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 00/03941

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	PATENT ABSTRACTS OF JAPAN vol. 009, no. 112 (C-281), 16 May 1985 (1985-05-16) -& JP 60 004189 A (SANKYO KK), 10 January 1985 (1985-01-10) abstract -----	1-13
X	PATENT ABSTRACTS OF JAPAN vol. 015, no. 154 (C-0825), 18 April 1991 (1991-04-18) -& JP 03 031286 A (SANKYO CO LTD), 12 February 1991 (1991-02-12) abstract -& DATABASE WPI Week 9112 Derwent Publications Ltd., London, GB; AN 1991-084514 XP002150083 (SANKYO CO LTD) abstract -----	1-13

INTERNATIONAL SEARCH REPORT

Information on patent family members

II Application No

PCT/EP 00/03941

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9935149	A	15-07-1999	AU 2615999 A		26-07-1999
US 4486425	A	04-12-1984	JP 1336735 C		11-09-1986
			JP 57169489 A		19-10-1982
			JP 61001074 B		13-01-1986
			JP 1058192 B		11-12-1989
			JP 1570557 C		25-07-1990
			JP 57206687 A		18-12-1982
			JP 57059894 A		10-04-1982
			AT 19403 T		15-05-1986
			AU 547984 B		14-11-1985
			AU 7578181 A		08-04-1982
			CA 1171404 A		24-07-1984
			DE 3174472 D		28-05-1986
			EP 0049118 A		07-04-1982
			ES 505923 D		16-12-1982
			ES 8302002 A		01-04-1983
			ES 514993 D		01-05-1983
			ES 8306158 A		01-08-1983
			ES 514994 D		01-05-1983
			ES 8306159 A		01-08-1983
			ES 514995 D		01-06-1983
			ES 8306759 A		16-09-1983
			FI 813038 A, B,		31-03-1982
			IE 53177 B		17-08-1988
			KR 8700848 B		25-04-1987
			MX 9203566 A, B		01-09-1992
			PH 18740 A		16-09-1985
			US 4716158 A		29-12-1987
			CA 1172248 A		07-08-1984
			DE 3173511 D		27-02-1986
			DE 3175700 D		22-01-1987
			EP 0049119 A		07-04-1982
			EP 0134420 A		20-03-1985
			ES 505922 D		01-01-1983
			ES 8302001 A		01-04-1983
			FI 813037 A, B,		31-03-1982
			KR 8700826 B		23-04-1987
			PH 16994 A		04-05-1984
			US 4483855 A		20-11-1984
US 5461043	A	24-10-1995	AU 647307 B		17-03-1994
			AU 2218392 A		11-03-1993
			BR 9203464 A		13-04-1993
			CA 2077562 A		08-03-1993
			CN 1070405 A, B		31-03-1993
			CZ 282320 B		11-06-1997
			EG 20237 A		31-05-1998
			EP 0531875 A		17-03-1993
			FI 923966 A		08-03-1993
			HR 920310 A		31-08-1994
			HU 64544 A		28-01-1994
			IL 103064 A		05-12-1996
			JP 2667943 B		27-10-1997
			JP 5213969 A		24-08-1993
			MX 9205081 A		01-03-1993
			NO 302122 B		26-01-1998
			NZ 244224 A		27-04-1995

INTERNATIONAL SEARCH REPORT

Information on patent family members

In application No

PCT/EP 00/03941

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 5461043 A		PL 171644 B		30-05-1997
		SI 9200204 A		31-03-1993
		SK 276192 A		06-05-1998
		RU 2075480 C		20-03-1997
		US 5550232 A		27-08-1996
		US 5614623 A		25-03-1997
		ZA 9206710 A		28-04-1993
JP 60004189 A	10-01-1985	JP 1886857 C		22-11-1994
		JP 3032554 B		13-05-1991
JP 03031286 A	12-02-1991	NONE		